EX-99.1 2 dp106457_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MONTHLY OPERATING REPORT
File with Court and submit copy to United States Trustee within 20 days after end of month.

 

Submit copy of report to any official committee appointed in the case.

 

REQUIRED DOCUMENTS Form No. Document Attached

Explanation

Attached

Affidavit/Supplement Attached
Schedule of Cash Receipts and Disbursements MOR-1 X    
Schedule of Disbursements by Debtor Entity MOR-1a X    
Schedule of Debtor Bank Account Balances MOR-1b X    
Schedule of Professional Fees and Expenses Paid MOR-1c X    
Copies of bank statements       Certification Attached
Cash disbursements journals       Certification Attached
Bank reconciliation       Certification Attached
Statement of Operations MOR-2 X    
Balance Sheet MOR-3 X    
Status of Postpetition Taxes       Certification Attached
Copies of IRS Form 6123 or payment receipt       Certification Attached
Copies of tax returns filed during reporting period       Certification Attached
Summary of Unpaid Postpetition Debts        
Summary of Unpaid Post Petition Accounts Payables MOR-4 X    
Accounts Receivable Aging MOR-5 X    
Debtor Questionnaire MOR-5 X    

 

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

 

/s/ Glenn Whaley   April 30, 2019
Signature of Authorized Individual*   Date

 

Glenn Whaley   VP Finance, Principal Financial and Accounting Officer
Printed Name of Authorized Individual   Title of Authorized Individual

 

*Authorized individual must be an officer, director or shareholder if debtor is a corporation; a partner if debtor
is a partnership; a manager or member if debtor is a limited liability company.

 

Notes: 

The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, as applicable, are: Pernix Sleep, Inc. (1599), Cypress Pharmaceuticals, Inc. (1860), Gaine, Inc. (3864), Hawthorn Pharmaceuticals, Inc. (2769), Macoven Pharmaceuticals, L.L.C. (4549), Pernix Holdco 1, LLC, Pernix Holdco 2, LLC, Pernix Holdco 3, LLC, Pernix Ireland Limited, Pernix Ireland Pain Designated Activity Company, Pernix Manufacturing, LLC (1236), Pernix Therapeutics Holdings, Inc. (4736), Pernix Therapeutics, LLC (1128) and Respicopea, Inc. (1303). The Debtor’s mailing address for purposes of this chapter 11 case is 10 North Park Place Suite 201, Morristown, NJ 07960.

 

 

 

UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

CERTIFICATION REGARDING POST-PETITION BANK ACCOUNT
RECONCILIATIONS, CASH DISBURSEMENT JOURNALS AND
COMPLIANCE AND PAYMENT OF POST-PETITION TAXES

 

I, Glenn Whaley, VP Finance, Principal Financial and Accounting Officer, of Pernix Sleep, Inc. et al. (the “Debtors”) hereby certify the following:

 

1. Attached to MOR-1 is a listing of the Debtor’s bank accounts, by account number, and the opening and closing balances. These accounts are reconciled monthly in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

 

2. Cash disbursement journals are maintained in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

 

3. To the best of my knowledge and belief, the Debtor is current on all post-petition taxes, and no post-petition tax amounts are past due.

 

/s/ Glenn Whaley   April 30, 2019
Signature of Authorized Individual*
VP Finance, Principal Financial and Accounting Officer

 

  Date

 

 

 

UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

Notes to Monthly Operating Report

 

Debtor in Possession Financial Statements 

The financial statements and supplemental information presented in this Monthly Operating Report (“MOR”) have been prepared using the Debtors’ books and records solely to comply with the monthly reporting requirements under the United States Bankruptcy Code and those of the United States Trustee for Region Three.

 

The financial statements and supplemental information presented herein are unaudited, preliminary in nature, and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects. These preliminary unaudited financial statements and other information represent the Debtor’s good faith attempt to comply with the requirements of the United States Bankruptcy Code and those of the United States Trustee using the resources available. This information is limited in scope to the requirements of this report.

 

These preliminary unaudited financial statements have not been subject to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP, and upon application of such procedures, the Debtors believe that the financial information could be subject to changes, which could be material. Certain totals may not sum due to rounding.

 

All related tax implications are not currently reflected in the preliminary unaudited financial statements herein. The financial impact of potential tax and other adjustments on the accompanying preliminary unaudited financial statements cannot be determined at this time.

 

There may be adjustments to the opening balance sheet as of February 17, 2019 that will impact these accompanying preliminary unaudited financial statements. ASC 805 permits a one-year measurement period in which the opening balance sheet can be adjusted if additional information becomes available.

 

Liabilities Subject to Compromise 

As a result of the commencement of the Debtors’ chapter 11 cases, the payment of certain prepetition indebtedness of the Debtors are subject to compromise or other treatment under a plan of reorganization.

 

Reorganization Items 

ASC 852 requires expenses and income directly associated with the Debtors’ chapter 11 cases to be reported separately in the income statement as reorganization items. Reorganization items include expenses related to legal advisory and representation services, and other professional consulting and advisory services. Reorganization costs also include adjustment to record debt at the estimated amount of the claim and an estimate of the loss on sale of assets which is pending a valuation.

 

Litigation 

The Debtors are subject to lawsuits and claims that arise out of its operations in the normal course of business.
Prior to the petition date, the Debtors were the defendant to various legal proceedings, described in detail in the most recent publicly filed financial statements, which are stayed during the course of the chapter 11 bankruptcy proceedings.

 

There are uncertainties inherent in any litigation and appeal and the Debtors cannot predict the outcome. At this time the Debtors are unable to estimate possible losses or ranges of losses that may result from such legal proceedings described in detail in the most recent publicly filed financial statements, and it has not accrued any amounts in connection with such legal proceedings in the financial statements herein, other than attorney’s fees accrued prior to the petition date.

 

 

3

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR – 1
Consolidated Schedule of Cash Receipts and Disbursements (1)
For the Period: February 18, 2019 - March 31, 2019
(Unaudited)

 

$ USD '000s  February 18, 2019 – March 31, 2019
   Pernix Therapeutics, LLC  Cypress Pharmaceuticals, Inc.  Pernix Ireland Limited  Pernix Ireland Pain
Designated Activity
Company
  Pernix Therapeutics Holdings, Inc.  Total
Beginning Cash Balance (Book)  $2,724   $3,322   $54   $172   $5   $6,276 
Receipts                              
Operating Receipts  $19,224   $2,391   $2   $-     $-      21,617 
Miscellaneous Receipts   -      -      -      -      -      -   
Total Receipts   19,224   $2,391    2              21,617 
Operating Disbursements                              
Payroll & Benefits   (1,101)   -      -      -      -      (1,101)
Gross to Net Disbursements   (10,945)   (466)   -      -      -      (11,411)
Inventory   (1,574)   (436)   -      (150)   -      (2,160)
Royalties   (156)   -      -      -      -      (156)
Insurance   (232)   -      -      -      -      (232)
Other G&A   (459)   (56)   (1)   (3)   -      (518)
Total Operating Disbursements   (14,466)   (959)   (1)   (153)   -      (15,579)
Operating Cash Flow   4,757    1,432    1    (153)   -      6,038 
Debt Service                              
ABL   -      -      -      -      (14,529)   (14,529)
Total Debt Service   -      -      -      -      (14,529)   (14,529)
Restructuring Costs                              
DIP Loan Interest and Fees   (131)   -      -      -      -      (131)
Professional Fees   (1,027)   -      -      -      -      (1,027)
Total Non-Operating Disbursements   (1,157)   -      -      -      -      (1,157)
                               
                               
Total Disbursements  $(15,624)  $(959)  $(1)  $(153)  $(14,529)  $(31,265)
Net Cash Flow  $3,600   $1,432   $1    (153)   (14,529)  $(9,648)
DIP Draw   4,000    -      -      -      14.529    18,529 
Nalpropion Escrow Transfer   (2,772)   -      -      -           (2,772)
Ending Cash Balance (Book)  $7,552   $4,754   $55   $19   $5   $12,384 
Nalpropion Escrow Account Cash Balance  $2,772   $-     $-     $-     $-     $2,772 

 

Notes: 

(1) The Schedule of Cash Receipts and Disbursements is presented on a book basis.

 

4

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR – la
Schedule of Disbursements by Debtor Entity(1)
For the Period: February 18, 2019 - March 31, 2019
(Unaudited)

 

$ USD '000s
Debtors
  Case Number  February 18, 2019 - March 31, 2019  Cumulative
Since Filing
Pernix Therapeutics, LLC  19-10329  $(15,624)  $(15,624)
Cypress Pharmaceuticals, Inc.  19-10330   (959)   (959)
Pernix Ireland Limited  19-10325   (1)   (1)
Pernix Ireland Pain Designated Activity Company  19-10327   (153)   (153)
Pernix Therapeutics Holdings, Inc.(2)  19-10324   (14,529)   (14,529)
Gaine, Inc.  19-10335   -      -   
Hawthorn Pharmaceuticals, Inc.  19-10336   -      -   
Macoven Pharmaceuticals, L.L.C.  19-10334   -      -   
Pernix Holdco 1, LLC  19-10331   -      -   
Pernix Holdco 2, LLC  19-10332   -      -   
Pernix Holdco 3, LLC  19-10326   -      -   
Pernix Manufacturing, LLC  19-10328   -      -   
Pernix Sleep, Inc.  19-10323   -      -   
Respicopea, Inc.  19-10333   -      -   
Total     $(31,265)  $(31,265)

 

Notes:

(1) The Schedule of Disbursements is presented on a book basis. The five entities included on the schedule represent all disbursements of the Debtors. The other remaining nine Debtor entities do not make disbursements.

(2) Pernix Therapeutics Holdings, Inc. disbursements includes the payoff of the pre-petition ABL and interest totaling $14,528,717.

 

5

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR - 1b
Schedule of Debtor Bank Account Balances (1)
For the Period: February 18, 2019 - March 31, 2019 (Unaudited)

 

$ USD '000s
Debtor
  Bank  Last Four Digits
Account No.
  Account Description  Beginning
Balance
2/18/2019
  Ending
Balance
3/31/2019
Pernix Therapeutics LLC  Wells Fargo  2816  Pernix zero-balance lockbox   -      -   
Cypress Pharmaceuticals, Inc.  Wells Fargo  5673  Cypress zero-balance lockbox   -      -   
Pernix Therapeutics LLC  Wells Fargo  2824  Pernix Operating   2,723,540    8,314,020 
Cypress Pharmaceuticals, Inc.  Wells Fargo  2865  Cypress Operating   3,321,777    4,754,921 
Pernix Therapeutics Holdings, Inc.  Wells Fargo  3388  Pernix Holdings   5,138    5,138 
Pernix Ireland Pain Designated Activity Company  Allied Irish Bank  3508  PIPDAC Operating   166,138    16,101 
Pernix Ireland Limited  Allied Irish Bank  8061  PIL Operating (EUR)(2)   53,746    55,108 
Pernix Ireland Pain Designated Activity Company  Allied Irish Bank  3187  PIPDAC Operating (EUR)(2)   5,515    3,069 
Pernix Therapeutics LLC  Wells Fargo  2840  Pernix Payroll   -      -   
Pernix Therapeutics LLC  Wells Fargo  2832  Pernix FSA   -      -   
Macoven Pharmaceuticals LLC  Wells Fargo  5186  Utility adequate assurance deposit   -      6,751 
Pernix Therapeutics LLC  Wells Fargo  0526  Nalpropion receipts escrow account   -      2,772,023 
Total Bank Account Balances           $6,275,854   $15,927,130 

 

Notes:

(1) The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts. 

(2) The EUR accounts are presented in USD and translated at the daily FX rate based upon the statement date.

 

6

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR - 1c
Schedule of Professional Fees and Expenses Paid
For the Period: February 18, 2019 - March 31, 2019
(Unaudited)

 

              

2/18/2019 - 3/31/2019

 

Cumulative Since Filing

Payee  Category  Payor  Date  Period Covered   Fees    Expenses    Fees    Expenses 
Retained Professionals                                
Prime Clerk LLC  Claims Agent  Pernix Therapeutics, LLC  3/15/2019  2/18/2019 - 2/28/2019  $24,254   $29,102   $24,254   $29,102 
Other Restructuring Professionals                                
Skadden, Arps, Slate, Meagher & Flom LLP  DIP Lenders Counsel  Pernix Therapeutics, LLC  3/11/2019  1/1/2019 - 2/18/2019   861,451    11,747    861,451    11,747 
Ducera Partners LLC  DIP Lenders Financial Advisor  Pernix Therapeutics, LLC  3/18/2019  3/1/2019 - 3/31/2019   100,000    311    100,000    311 
Total              $985,705   $41,160   $985,705   $41,160 

 

7

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR - 2
Statement of Operations
For the Period: February 18, 2019 - March 31, 2019
(Unaudited)

 

$ USD '000s  February 18 - March 31, 2019
   Pernix Therapeutics,
LLC
  Cypress
Pharmaceuticals, Inc.
  Pernix Ireland Limited  Pernix Ireland Pain
Designated Activity
Company
  Intercompany Eliminations  Pernix Therapeutics
Holdings, Inc.
  Total
                      
Net product sales  $6,920   $934   $-     $1,265   $(1,265)  $-     $7,854 
Cost of product sales   (1,805)   (1,397)   (81)   (1,272)   2,073    -      (2,482)
Operating expenses:                                   
Selling, general and administrative   (5,541)   (314)   (1)   (16)   210    (16)   (5,679)
Amortization of product rights   (12)   (58)   -      (676)   -      -      (746)
Other operating expenses   (83)   -      -      -      -      -      (83)
Total operating expenses   (5,637)   (373)   (1)   (691)   210    (16)   (6,508)
Gain/(Loss)from operations   (521)   (836)   (82)   (698)   1,018    (16)   (1,135)
                                    
Other income/(expense):                                   
Interest income   -      -      -      43    (2,090)   2,090    43 
Interest expense   (4)   -      (2,090)   (1,057)   2,090    (3,429)   (4,489)
Management fee income   298    -      -      -      -      -      298 
Other income/(expense)   0    -      (0)   (0)   -      -        
Total other income (expenses)   295    -      (2,090)   (1,014)   -      (1,339)   (4,148)
Net gain/(loss)   (226)   (836)   (2,172)   (1,712)   1,018    (1,356)   (5,283)
Reorganization expenses   (302)   -      -      -      -      -      (302)
Net gain/(loss)  $(528)  $(836)  $(2,172)  $(1,712)  $1,018   $(1,356)  $(5,585)

 

8

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR - 3
Balance Sheet
(Unaudited)

 

$ USD '000s  As of March 31, 2019
  

Pernix Therapeutics,
LLC(1)

  Cypress
Pharmaceuticals, Inc.
  Pernix Ireland Limited  Pernix Ireland Pain
Designated Activity
Company
  Intercompany Eliminations  Pernix Therapeutics
Holdings, Inc.
  Total
Assets                     
Current assets:                                   
Cash and cash equivalents  $7,552   $4,754   $55   $19   $-     $5   $12,384 
Restricted cash   2,779    -      -      -      -      -      2,779 
Accounts receivable, net   25,742    10,743    106,007    11,884    (117,891)   -      36,486 
Inventory   4,645    6,193    168    -      (6,941)   -      4,065 
Prepaid expenses and other current assets   6,201    83    13    486    (72,000)   72,586    7,369 
Intercompany receivable   153,042    8,963    (282,167)   (7,251)   -      130,655    3,242 
Total current assets   199,962    30,735    (175,924)   5,138    (196,832)   203,246    66,324 
Non-current assets:                                   
Property and equipment, net   421    3    10    -      -      -      434 
Investments   -      -      -      4,428    (109,815)   109,815    4,428 
Intangible assets   11,095    2,875    0    39,556    -      -      53,526 
Goodwill   196    6,457    2,825    2,621    -      -      12,100 
Related party loan receivable   -      -      -      4,584    -      -      4,584 
Other long-term assets   190    -      -      -      -      1,339    1,529 
Total assets  $211,864   $40,070   $(173,089)  $56,326   $(306,648)  $314,401   $142,925 
Liabilities and Stockholders' Equity                                   
Current liabilities:                                   
Accounts payable   2,811    693    72    2    -      -      3,578 
Accrued expenses   42,053    11,780    81    -      -      -      53,913 
Related party payable   3,641    -      -      -      -      -      3,641 
Other liabilities   838    -      296    -      -      -      1,134 
DIP loan   -      -      -      -      -      18,529    18,529 
Total current liabilities:   49,342    12,473    449    2    -      18,529    80,794 
Total liabilities not subject to compromise   49,342    12,473    449    2    -      18,529    80,794 
Total liabilities subject to compromise   124,794    16,106    72,586    52,627    (189,891)   236,017    312,239 
Stockholders' equity/(deficit)   37,728    11,491    (246,124)   3,697    (116,756)   59,856    (250,109)
Total liabilities and stockholders' equity/(deficit)  $211,864   $40,070   $(173,089)  $56,326   $(306,648)  $314,401   $142,925 

 

Notes: 

(1) The Pernix Therapeutics, LLC with Pernix Sleep, LLC intercompany transaction is not included in the above balance sheet presentation. This analysis was completed in connection with the SOFAs/SOALs filed on April 2, 2019. However, to be aligned with the Company’s books and records this was not completed for the MOR.

 

9

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR – 3
Balance Sheet
(Unaudited)

 

$ USD '000s  As of February 17, 2019
  

Pernix Therapeutics,
LLC(1)

  Cypress
Pharmaceuticals, Inc.
  Pernix Ireland
Limited
  Pernix Ireland Pain
Designated Activity
Company
  Intercompany
Eliminations
  Pernix Therapeutics
Holdings, Inc.
  Total
Assets                     
Current assets:                                   
Cash and cash equivalents  $2,724   $3,322   $54   $172   $-     $5   $6,276 
Restricted cash   -      -      -      -      -      -      -   
Accounts receivable, net   25,288    12,459    106,007    10,619    (116,626)   -      37,747 
Inventory   5,335    7,309    168    -      (7,960)   -      4,852 
Prepaid expenses and other current assets   6,840    83    14    641    (69,911)   70,503    8,171 
Intercompany receivable   155,249    9,200    (282,167)   (5,972)   -      126,786    3,095 
Total current assets   195,437    32,372    (175,924)   5,459    (194,496)   197,294    60,142 
Non-current assets:                                   
Property and equipment, net   500    3    10    -      -      -      513 
Investments   -      -      -      4,428    (109,815)   109,815    4,428 
Intangible assets   11,108    2,933    0    40,231    -      -      54,272 
Goodwill   196    6,457    2,825    2,621    -      -      12,100 
Related party loan receivable   -      -      -      4,584    -      -      4,584 
Other long-term assets   190    -      -      -      -      1,407    1,597 
Total assets  $207,430   $41,766   $(173,089)  $57,324   $(304,311)  $308,516   $137,636 
Liabilities and Stockholders' Equity                                   
Current liabilities:                                   
Accounts payable  $150   $-     $71   $399   $-     $-      620 
Accrued expenses   38,944    12,922    -      -      -      -      51,866 
Related party payable   -      -      -      -      -      -      -   
Other liabilities   913    -      296    -      -      -      1,209 
DIP loan   -      -      -      -      -      14,185    14,185 
Total current liabilities:   40,007    12,922    367    399    -      14,185    67,880 
Total liabilities not subject to compromise   40,007    12,922    367    399    -      14,185    67,880 
Total liabilities subject to compromise   129,171    16,517    70,496    51,515    (186,537)   233,120    314,283 
Stockholders' equity/(deficit)   38,253    12,327    (243,952)   5,409    (117,775)   61,211    (244,527)
Total liabilities and stockholders' equity/(deficit)  $207,430   $41,766   $(173,089)  $57,324   $(304,311)  $308,516   $137,636 

 

Notes: 

(1) The Pernix Therapeutics, LLC with Pernix Sleep, LLC intercompany transaction is not included in the above balance sheet presentation. This analysis was completed in connection with the SOFAs/SOALs filed on April 2, 2019. However, to be aligned with the Company’s books and records this was not completed for the MOR.

 

10

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR-4
Summary of Unpaid Post Petition Accounts Payables
As of March 31, 2019
(Unaudited)

 

$ USD '000s

                  
   Number of Days Past Due
Post Petition Accounts Payable Aging  Current  0-30(2)  31-60  61-90  Over 90  Total
Post-Petition Accounts Payable(1)  $1,655   $2   $-     $-     $-     $1,657 
  $1,655   $2   $-     $-     $-     $1,657 

 

Notes: 

(1) The above figures represent post petition trade payables recorded in the Debtors’ subledger.
(2) The $2K amount that was past due at March 31, 2019 was due to an ordinary course professional that was not yet approved to be paid.

 

11

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: February 18, 2019 - March 31, 2019

 

MOR-5
Accounts Receivable Aging
As of March 31, 2019
(Unaudited)

 

$ USD '000s 

                  
   Number of Days Past Due
Accounts Receivable Aging  Current  0-30 Days  31-60 Days  61-90 Days  91 Days+  Total
Accounts Receivable, net  $21,206   $11,953   $1,595   $1,475   $257   $36,486 
  $21,206   $11,953   $1,595   $1,475   $257   $36,486 

 

Debtor Questionnaire

 

Must be completed each month Yes No

1.

 

Have any assets been sold or transferred outside the normal course of business
this reporting period?  If yes, provide an explanation below.
X  

2.

 

Have any funds been disbursed from any account other than a debtor in possession
account this reporting period?  If yes, provide an explanation below.
  X

3.

 

Have all post petition tax returns been timely filed? If no, provide an explanation
below.
X  

4.

 

Are workers compensation, general liability and other necessary insurance
coverages in effect?  If no, provide an explanation below.
X  

5.

 

Has any bank account been opened during the reporting period? If yes, provide
documentation identifying the opened account(s). If an investment account has been
opened provide the required documentation pursuant to the Delaware Local Rule 4001-3. 

X  

 

Notes: 

1) The Debtors sold office furniture and fixtures in connection with ending the South Carolina office space lease.
5) Wells Fargo account 0526 was opened during this period as an escrow account to hold Nalpropion operating receipts.

 

12

 

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

 

In re: 

 

PERNIX SLEEP, INC., et al.1 

 

Debtors. 

Chapter 11 

 

Case No. 19-10323 (CSS) 

 

Jointly Administered 

 

 

AFFIDAVIT OF SERVICE

 

STATE OF DELAWARE )  
  ) SS
NEW CASTLE COUNTY )  

 

Melissa Ramirez, being duly sworn according to law, deposes and says that she is employed by the law firm of Landis Rath & Cobb LLP, Delaware counsel to the Debtors and Debtors in Possession in the above referenced case, and on the 1st day of May, 2019, she caused a copy of the following:

 

MONTHLY OPERATING REPORT
February 18, 2019 through March 31, 2019

 

to be served upon the party identified below in the manner so indicated;

 

Via Hand Delivery
Office of the U.S. Trustee
Attn: Benjamin Hackman, Esquire
844 N. King Street
Suite 2207, Lockbox 35
Wilmington, DE 19801

 

/s/ Melissa Ramirez
Melissa Ramirez

 

 

SWORN TO AND SUBSCRIBED before me this 1st day of May, 2019.

 

/s/ Darcy Snyder
Notary Public
My Commission Expires: 11-16-2020
 

 

 

1 The Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, where applicable, are: Pernix Therapeutics Holdings, Inc. (4736), Pernix Therapeutics, LLC (1128), Pernix Manufacturing, LLC (1236), Pernix Sleep, Inc. (1599), Cypress Pharmaceuticals, Inc. (1860), Hawthorn Pharmaceuticals, Inc. (2769), Macoven Pharmaceuticals, L.L.C. (4549), Gaine, Inc. (3864), Respicopea, Inc. (1303), Pernix Ireland Limited (3106PH), Pernix Ireland Pain Designated Activity Company (0190LH), Pernix Holdco 1, LLC, Pernix Holdco 2, LLC, Pernix Holdco 3, LLC.

 

13